# A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

> **NCT05923008** · PHASE1,PHASE2 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 182 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IBI130

## Key facts

- **NCT ID:** NCT05923008
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-14
- **Primary completion:** 2024-11-30
- **Final completion:** 2026-10-31
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923008, "A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05923008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*